- The trial: CorCal Outcomes randomised 5,772 adults (mean age 64) with no heart disease, diabetes or statin use to statin advice based on a coronary artery calcium (CAC) scan or on the standard risk calculator (ESC Congress 2026)
- Same event rate: after 4.2 years, heart attacks, strokes, artery-opening procedures and deaths added up to 2.7% in both groups
- Fewer statins, better adherence: the risk-score group was advised to start a statin more than three times as often, and people advised by their scan were far more likely to take it: 62% vs 23%
- But it didn't prove the scan is as safe. Fewer events than expected left the result too uncertain: the plausible range ran from about 29% fewer events to 38% more with the scan approach, and the non-inferiority criterion was not met
- For you: a calcium scan is a reasonable tiebreaker if your risk is in the grey zone, as guidelines already say, not a proven replacement for the usual assessment. Talk to your doctor
A headline this week says a major trial "challenges how doctors decide who really needs statins." The results were first presented in August, and the headline runs ahead of them. Letting a heart scan decide led to far fewer statin recommendations, much better adherence and the same rate of heart events over four years. It did not show the scan approach is as protective, because the trial ended up too small to tell. It isn't medical advice.
What CorCal Actually Tested
Evidence: Randomised trial — underpowered; conference results, not yet published in fullCorCal Outcomes was run by Intermountain Health in Utah. The results were presented by principal investigator Joseph B. Muhlestein of Intermountain Medical Center in Murray; Jeffrey L. Anderson, the design paper's first author, co-leads the trial. Patients registered with Intermountain's Canyons and Desert regions who had no known atherosclerotic cardiovascular disease, no diabetes and had never taken a statin were randomised 1:1 to one of two ways of deciding about statins (ESC press release):
- Risk-score arm: the pooled cohort equations (PCE), the US calculator that turns age, sex, cholesterol, blood pressure, diabetes and smoking into a 10-year risk estimate, applied under the then-current US (AHA/ACC) guidelines.
- Scan arm: a coronary artery calcium scan, with the statin recommendation based on a CAC risk algorithm.
In both arms, patients and their doctors received a protocol-directed recommendation, and they "made the final treatment decisions." The registry lists it as an open-label, pragmatic trial, with men aged 50 to 80 and women aged 60 to 80 eligible (NCT03439267). The design paper, published in the American Heart Journal in 2026, reports that 75,539 patients were screened by medical record and invited at random between October 2019 and March 2025; 5,772 agreed and were randomised (2,886 per arm), with an average age of 64.3 and 51.5% women. The primary analysis was "modified per-protocol": it included the 5,329 people who completed baseline testing and received a recommendation (Anderson, Am Heart J 2026).
The primary outcome was major adverse cardiovascular events (MACE): death from any cause, heart attack, stroke, or a procedure to reopen an artery. The question was whether scan-guided care was non-inferior: not meaningfully worse.
The results
Results were presented in a Hot Line session at the European Society of Cardiology Congress in Munich on 31 August 2026 (ESC; ACC). After 4.2 years of follow-up:
- Events: MACE occurred in 2.7% of patients in both groups (hazard ratio 0.99; 95% confidence interval 0.71 to 1.38). "The noninferiority criterion was not met."
- Statin advice: the risk-score group "received a recommendation to initiate statins more than three times as frequently" as the scan group. The press materials give no final percentages.
- Adherence: people recommended a statin on the basis of their calcium score "were much more adherent with their medication than those in the PCE group (62% vs. 23%)", about 2.7 times as high.
Earlier figures, presented in March 2025 when 5,615 people had enrolled, give a sense of the gap: 50.7% of the risk-score arm were recommended a statin and another 21.7% told to consider one, against 22.3% in the scan arm. Intermountain linked it to the calculator's heavy weighting of age: many older people have a zero or low calcium score (Intermountain, via News-Medical).
Risk score vs calcium scan: three numbers
Events and adherence: ESC press release, ESC Congress 2026 (hazard ratio for events 0.99, 95% CI 0.71 to 1.38). Statin recommendations: enrolment-phase figures from 5,615 patients, presented March 2025 (Intermountain); the final results say only that the risk-score arm was advised to start statins "more than three times as frequently." How adherence was measured was not described in the press materials.
What "Non-inferiority Not Established" Means
Evidence: Inconclusive on safety — promising on adherenceTo pass a non-inferiority test, a trial must show that even the worst plausible result for the new approach stays inside a margin set in advance.
Identical event rates failed because there were few events. The hazard ratio of 0.99 means essentially no difference, but the 95% confidence interval, 0.71 to 1.38, is the range the data can't rule out. At one end, the scan approach could mean about 29% fewer events; at the other, about 38% more. Muhlestein said: "we did not demonstrate noninferiority between the groups," and "The power of the study to detect a difference was reduced by the lower-than-expected event rates" (ESC). He described the results as "hypothesis-generating" and said they could help plan a larger trial (ACC).
One oddity: the press release lists "p=0.045 for noninferiority" while saying the criterion wasn't met. Neither the press materials nor the design paper's summary give the pre-set margin or significance threshold, so go by the investigators' own summary: not proven.
Other things to keep in mind
- Conference data. We couldn't find the outcome results in a peer-reviewed journal yet; the ESC release cites none. Key details, including the scan algorithm's cut-offs and how adherence was measured, aren't in the press materials.
- One health system, in Utah and the Mountain West, and only men aged 50 to 80 and women aged 60 to 80.
- The comparator has moved on. The 2026 US guideline now recommends the newer PREVENT equations over the pooled cohort equations for adults aged 30 to 79 (ACC), so CorCal compared the scan with yesterday's calculator.
- Adherence cuts both ways. With only 23% of people advised a statin in the risk-score arm taking it, many extra recommendations never became treatment, which may help explain why outcomes looked alike.
Why might a scan help adherence? Seeing your own plaque may persuade more than a percentage. A 2017 meta-analysis of 6 studies (11,256 participants) found that people with a calcium score above zero were more likely to start lipid-lowering medication (odds ratio 2.9) and to keep taking it (2.3) than people with a zero score (Gupta, JACC Cardiovasc Imaging 2017). Those were observational comparisons; CorCal adds randomised evidence. If muscle aches are what puts people off, our piece on statin muscle aches covers why most of them turn out not to be the statin.
What a Calcium Score Tells You
Evidence: Strong for risk prediction — large cohortsA CAC scan is a quick, non-contrast CT of the heart that measures calcified plaque in the coronary arteries. The result is reported in Agatston units, after the method Arthur Agatston and colleagues described in 1990 (Agatston, JACC 1990). Zero means no calcified plaque was seen; higher numbers mean more. Some reports also give a percentile, comparing your score with similar people; the 2018 US guideline treats the 75th percentile or above as one threshold for treatment.
Radiation. In 3,442 participants of the Multi-Ethnic Study of Atherosclerosis (MESA), the average effective dose was 1.05 mSv (median 0.95), higher in people over 75 and those with severe obesity. The authors concluded that with modern scanners the dose "is approximately 1 mSv" (Messenger, Int J Cardiovasc Imaging 2016).
Cost. GoodRx puts the price at $100 to $400, with an average out-of-pocket cost of about $100 to $150, and notes that most insurance plans, including Medicare, typically don't cover it (GoodRx, 2025).
What zero means. Not clean arteries: the scan sees only calcified plaque, so soft, early plaque is missed, which matters most in younger people (see our article on silent plaque and apoB). But zero points to low short-term risk, and it's common. In a 2015 MESA analysis of 4,758 adults, 44% of those eligible for a statin under the 2013 US guidelines had a score of zero, and their heart event rate over 10 years was 4.2 per 1,000 person-years. "The absence of CAC reclassifies approximately one-half of candidates as not eligible for statin therapy," the authors wrote (Nasir, JACC 2015). That is the logic CorCal set out to test.
What a calcium score means for statin decisions
| CAC score | 2018 US cholesterol guideline adults at intermediate risk | 2026 US guideline |
|---|---|---|
| 0 | Statin "may be withheld or delayed" except smokers, diabetes, strong family history of early heart disease | Statin may be deferred per guideline summaries; not in ACC summary |
| 1–99 | "Favors statin therapy, especially in those ≥55" | Any calcium supports LDL goal <100 mg/dL |
| ≥100 or ≥75th percentile | "Statin therapy is indicated" | Lower LDL targets with higher amounts of calcium cut-offs not given in ACC summary |
| Who should be scanned | Adults at intermediate 10-year risk (7.5% to <20%) and selected adults at borderline risk | "Selective use" for men over 40 and women over 45 at borderline or intermediate risk |
2018: Grundy et al., AHA/ACC cholesterol guideline, as summarised by the American College of Cardiology (2019). 2026: ACC/AHA dyslipidemia guideline, ACC summary (13 March 2026), with the CAC 0 row from EBSCO DynaMed's summary; risk estimated with PREVENT, borderline 3% to <5% and intermediate 5% to <10% 10-year risk. In Europe, the 2025 ESC/EAS focused update says a measured CAC score should be considered a risk modifier in people at moderate risk or near treatment thresholds.
Where Scans Fit in the Guidelines
Evidence: Guideline-endorsed as a tiebreaker — not as screening for everyoneThe 2018 US cholesterol guideline said that in adults at intermediate risk (a 10-year risk of 7.5% to under 20%), "if CAC is zero, treatment with statin therapy may be withheld or delayed," with exceptions for smokers, people with diabetes and those with a strong family history of early heart disease, and that at 100 or more "statin therapy is indicated" (ACC, on the 2018 guideline).
The 2026 ACC/AHA dyslipidemia guideline, published in March, kept the scan in the same role. It recommends "selective use" of a non-contrast CAC scan "for men over the age of 40" and "women over the age of 45 with borderline or intermediate 10-year risk of heart attack or stroke," and says "having any amount of CAC supports an LDL-C goal of <100 mg/dL," with lower targets for higher scores (ACC). In Europe, the 2025 ESC/EAS focused update says a measured CAC score "should be considered as a risk modifier in individuals at moderate risk" (ESC). Both treat the scan as a grey-zone tiebreaker. CorCal tested the bolder idea of letting the scan lead, and couldn't settle it.
Scanning everyone: the DANCAVAS trial
DANCAVAS randomised 46,611 Danish men aged 65 to 74 either to an invitation for screening that included a heart CT (calcium score, plus checks for aortic aneurysm and atrial fibrillation), an ankle blood pressure check and blood tests, or to no invitation; 62% of those invited were screened. After a median of 5.6 years, 12.6% of the invited group and 13.1% of the control group had died (hazard ratio 0.95; 95% CI 0.90 to 1.00), not a significant difference. A secondary combined outcome of death, stroke or heart attack was lower (hazard ratio 0.93), and a prespecified subgroup of men aged 65 to 69 did better (Healio, on Lindholt, NEJM 2022; ACC). It hints at benefit without proving it.
Who Might Ask About a Scan
- It's most useful when you're on the fence. If your doctor says your 10-year risk is borderline or intermediate and you're unsure about starting a statin, ask whether a calcium scan would change the decision. That's the group the 2026 US guideline names: men over 40 and women over 45.
- It usually won't help if the answer is already clear. If you've had a heart attack or stent, or have diabetes or very high LDL, talk to your doctor about treatment rather than a scan. The 2018 guideline didn't let a zero score override smoking, diabetes or a strong family history.
- A zero is reassuring, not a free pass. It doesn't measure soft plaque, so blood pressure, apoB, blood sugar, smoking and fitness still count.
- A positive score is a reason to act, and to keep acting. If your scan shows calcium, talk to your doctor about your LDL target and stick with the plan you agree.
- Don't stop a statin because of these headlines. CorCal enrolled people who had never taken one. Discuss any change with your doctor.
Frequently Asked Questions
A useful tiebreaker, not yet a replacement.
CorCal suggests that letting a calcium scan guide statin decisions targets treatment at fewer people, and that those people are much more likely to take it, with no sign of extra heart events over four years. But fewer events than expected left the trial unable to prove the scan approach is as protective as the usual one.
If your risk sits in the grey zone, a calcium scan is a reasonable question for your doctor. If you're already on a statin, or your risk is clearly high, these results aren't a reason to change course without that conversation.
Sources
- European Society of Cardiology. New data presented on the use of coronary artery calcium for cardiovascular risk assessment. Press release, ESC Congress 2026, Munich, 31 August 2026 (CorCal Outcomes, Hot Line session; principal investigator Joseph B. Muhlestein). Also via EurekAlert! and ScienceDaily.
- American College of Cardiology. CorCal Outcomes, EVAOLD, ISOLEDS inform CV risk prediction, post-MI treatment and stenting strategies. ESC Congress 2026 coverage, 31 August 2026.
- Anderson JL, May HT, Winslow T, Le VT, Iverson L, Bair TL, Knowlton KU, Muhlestein JB. CorCal Outcomes: a randomized trial using the pooled cohort equation or coronary artery calcium to select statin therapy in primary prevention patients. American Heart Journal 2026;299:107473 (doi:10.1016/j.ahj.2026.107473). Trial registration NCT03439267.
- Intermountain Health. Study aims to determine best method for statin prescription in coronary heart disease. Enrolment-phase CorCal data presented at ACC.25, 29 March 2025, via News-Medical. See also KUTV, 2025.
- American College of Cardiology. ACC/AHA release new clinical guideline for managing dyslipidemia. 13 March 2026. Summary of the 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia, JACC (doi:10.1016/j.jacc.2025.11.016).
- EBSCO DynaMed (DeGeorge K). Top takeaways from the updated ACC/AHA guideline on the management of dyslipidemia. EBM Focus, 2026 ("Statin therapy may be deferred for CAC = 0"). See also Valley Medical Center, 2026 lipid guideline summary.
- American College of Cardiology. 2018 cholesterol guideline and the judicious use of coronary calcium score: what does a cardiologist need to know? 20 August 2019. On Grundy SM, Stone NJ, et al., 2018 AHA/ACC multisociety guideline on the management of blood cholesterol, J Am Coll Cardiol 2018.
- Mach F, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal 2025;46:4359–4378. As cited in the ESC press release (source 1).
- Gupta A, Lau E, Varshney R, et al. The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis. JACC: Cardiovascular Imaging 2017;10(8):833–842 (doi:10.1016/j.jcmg.2017.01.030).
- Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. Journal of the American College of Cardiology 1990;15(4):827–832 (doi:10.1016/0735-1097(90)90282-T).
- Messenger B, Li D, Nasir K, Carr JJ, Blankstein R, Budoff MJ. Coronary calcium scans and radiation exposure in the Multi-Ethnic Study of Atherosclerosis. International Journal of Cardiovascular Imaging 2016;32(3):525–529 (doi:10.1007/s10554-015-0799-3).
- GoodRx. How much does a coronary artery calcium scan cost? 28 August 2025.
- Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA. Journal of the American College of Cardiology 2015;66(15):1657–1668 (doi:10.1016/j.jacc.2015.07.066).
- Lindholt JS, et al. Five-year outcomes of the Danish Cardiovascular Screening (DANCAVAS) trial. New England Journal of Medicine 2022 (doi:10.1056/NEJMoa2208681). As reported by Healio and the American College of Cardiology.